Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. 16 April 2020. Joe Brennan.

Executive Summary

US regulators are allowing Dexcom and Abbott to bring their continuous glucose monitoring devices directly to hospitals for remote monitoring of COVID-19 patients. Here’s why telehealth consultant Joe Brennan, Moonshot Health Consulting, thinks this could open a new market opportunity post-pandemic.

“One, it allows [CGM] to be used within the four walls of the hospital. Two, when that patient is discharged, they already know how to use the device, they’re already comfortable with it. There is that continuity of care even after they are discharged from the hospital. It has potential to create a whole new market.”- Joe Brennan, telehealth consultant, Moonshot Health Consulting

Click here for a free trial of Medtech Insight

Related Content

Topics

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel